2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. E1/E2/E3 Enzyme
  5. Casitas B-lineage lymphoma-b Isoform

Casitas B-lineage lymphoma-b

Cbl-b

Cbl-b functions as an E3 ubiquitin ligase that regulates B-cell receptor (BCR) signaling and downstream activation of proliferative pathways in B lymphocytes[1][2][4]. Mechanistically, Cbl-b modulates antigen-induced BCR internalization and controls the amplitude of NF-κB, PI3K/Akt, and MAPK pathway activation, thereby influencing B-cell survival and proliferation[6][2][5]. In disease models, dysregulation of Cbl-b contributes to B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), where altered ubiquitination leads to enhanced oncogenic signaling[3][2][7]. Compared with related isoforms, Cbl-b exhibits distinct substrate specificity and regulatory roles, differing from Cbl and Cbl-c in modulating tonic versus antigen-dependent BCR signaling[1][4][5]. Experimental inhibition of Cbl-b can enhance BCR signaling in vitro, whereas agonist-like modulation has been explored to restrain hyperactive B-cell proliferation, suggesting potential applications for dissecting lymphomagenesis mechanisms[2][4][8]. Therefore, Cbl-b represents both a mechanistic node for B-cell activation and a practical target for studies of malignant B-cell regulation and therapy development[1][2][7].

Casitas B-lineage lymphoma-b Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-183293
    Cbl-b-IN-32
    		Inhibitor
    Cbl-b-IN-32 is a Cbl-b inhibitor with an IC50 of 6.83 μM. Cbl-b-IN-32 binds to the TKB-LH interface, stabilizes the inactive conformation of Cbl-b, engages Tyr363 via hydrogen bonds and water bridges, and forms hydrogen bonds with Phe261 and Phe263.
  • HY-159608
    PROTAC Cbl-b-IN-1
    		Degrader
    PROTAC Cbl-b-IN-1 (compound 64) is a potent Cbl-b PROTAC degrader with a DC50 of less than 30 nM. PROTAC Cbl-b-IN-1 can be used for cancer research.